Company intelligence / Profile preview
Juvaris BioTherapeutics
Burlingame, California, United Statesjuvaris.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Juvaris developed a novel adjuvant platform based on cationic lipid-non-coding DNA complexes, which demonstrated strong T-cell and antibody responses in preclinical models. Its lead adjuvant, JVRS‑100, reached Phase 2 clinical trials as an enhancer for seasonal flu vaccines in the elderly. The company also advanced proprietary vaccine candidates for influenza, hepatitis B, HSV‑2, and pneumonia. In 2011, all human health assets were exclusively licensed to Colby Pharmaceutical Company; animal health rights had been previously licensed to Bayer AG.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineAdjuvantLipid nanoparticle delivery therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Colby Pharmaceutical Company (exclusive licensee for human health applications since September 2011)Bayer AG (animal health rights licensee since ~2008)
Beyond the preview
Go deeper on Juvaris BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Juvaris BioTherapeutics.